News | January 14, 2015

Opsens Announces First use of FFR Products in Europe

OptoWire and OptoMonitor guide therapy in patients with coronary heart disease

FFR catheters, Cath lab, OptoWire, OptoMonitor

Image courtesy of Opsens


January 14, 2015 — Opsens Inc. announced the first use of its Fractional Flow Reserve (FFR) products in Europe by the founders of FFR, namely Bernard De Bruyne, M.D. at the Cardiovascular Center Aalst, Belgium and by professor Nico Pijls, at the Catharina Hospital, Eindhoven the Netherlands. The OptoWire and OptoMonitor are Opsens’ products for FFR measurements to optimize the diagnosis and guide the therapy in patients with coronary heart disease.

"The arrival of an optical FFR guidewire such as the OptoWire on the market is positive for interventional cardiologists who need to obtain reliable FFR measurements. It allowed me to appreciate its zero drift performance during all cases performed while also acknowledging the constant connection reliability as well as its support during percutaneous coronary intervention", said Bernard De Bruyne, M.D., from the Cardiovascular Center Aalst.

The OptoWire provides intra-coronary blood pressure measurements with optical pressure guidewire technologies. It is immune to adverse effects related to blood contact, and allows easy connectivity that leads to reliable FFR measurements in extended conditions of usage. The product is designed to provide cardiologists with a guidewire delivering optimized performances to navigate coronary arteries and reach blockages. Based on industry sources, the FFR market represented more than $250 million in U.S. sales in 2013 and is expected to reach $1 billion in the medium-term.  

For more information: www.opsens.com

 


Related Content

Feature | Cath Lab | Kyle Hardner

Since receiving FDA approval in 2016, intravascular lithotripsy (IVL) systems have grown in popularity among ...

Home November 14, 2025
Home
News | Cath Lab

Nov. 11, 2025 — FastWave Medical has successfully completed enrollment in its 30-patient coronary feasibility study and ...

Home November 13, 2025
Home
News | Cath Lab

Oct. 28, 2025 — Results from the first-of-its-kind randomized PROCTOR trial found that a strategy of saphenous vein ...

Home November 04, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Results from the PREVUE-VALVE study suggest that there are currently at least 4.7 million people aged 65 ...

Home October 29, 2025
Home
News | Cath Lab

Oct. 25, 2025 — Medtronic plc has announced the launch of the Stedi Extra Support guidewire, designed to enhance ...

Home October 28, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Elixir Medical, a developer of technologies to treat cardiovascular disease, has announced new clinical ...

Home October 28, 2025
Home
News | Cath Lab

Oct. 22, 2025 — Heartflow, Inc. has introduced Heartflow PCI Navigator, the newest addition to the Heartflow One ...

Home October 23, 2025
Home
News | Cath Lab

Oct. 15, 2025 — Stereotaxis recently announced it has obtained CE Mark in Europe and submitted a 510(k) application to ...

Home October 16, 2025
Home
News | Cath Lab

Oct. 7, 2025 — Medtronic has announced the full distribution of the Neuroguard IEP System (Neuroguard) after a ...

Home October 07, 2025
Home
News | Cath Lab

Sept. 22, 2025 — Nicklaus Children's Heart Institute in Miami, Florida, is now offering bedside transcatheter patent ...

Home September 23, 2025
Home
Subscribe Now